Clinical effects of scaling and root planing in adults infected with Actinobacillus actinomycetemcomitans

Abstract Background: The aim of this triple- blind placebo- controlled parallel- arm randomized clinical trial was to evaluate the clinical effects of Lactobacillus rhamnosus SP1 or azithromycin as an adjunct to scaling and root planing (SRP) in patients with stage III periodontitis.Methods: Forty-seven systemically healthy participants with stage III periodontitis were recruited. Following SRP, the participants were randomly assigned to one of three treatment modalities; 1) placebo (n=15), 2) probiotics (n=16) and 3) antibiotics-azithromycin (n=16). The participants were monitored at baseline, 3, 6, 9 and 12 months after therapy. Probing pocket depth (PPD), bleeding on probing (BOP), clinical attachment loss (CAL) and plaque accumulation (PI) were evaluated. Results: All 47 participants completed the study. At 12 months, all groups showed significant improvements of PPD and PI (p<0.012) irrespective of the treatment modality and without significant differences between the groups. Probiotics and azithromycin showed no added benefit in terms of CAL. While the placebo (p=0.002) and the antibiotic-azithromycin (p=0.002) group showed a significant reduction of BOP, only the placebo group revealed a significant reduction of CAL at 12 months follow-up (p=0.003). The number of sites and teeth with PPD ≥5, ≥6 and ≥7mm were significantly reduced in all groups at 12 months follow-up (p<0.025) irrespective of the treatment regime and without significant differences between the groups. Conclusion: The use of probiotics or azithromycin as an adjunct to SRP failed to provide additional benefits in the treatment of stage III periodontitis. The benefits of these two treatment regimes as an adjunct to SRP remain unclear.

Download Full-text

Clinical effects of scaling and root planing on untreated teeth

Journal Of Clinical Periodontology ◽

10.1111/j.1600-051x.2004.00626.x ◽

2005 ◽

Vol 32 (1) ◽

pp. 21-28 ◽

Cited By ~ 17

Author(s):

Adrian P. Pawlowski ◽

Allen Chen ◽

Beth M. Hacker ◽

Lloyd A. Mancl ◽

Roy C. Page ◽

...

Keyword(s):

Clinical Effects ◽

Scaling And Root Planing ◽

Root Planing

Download Full-text

Clinical Effects of Probiotic or Azithromycin as an Adjunct to Scaling and Root Planing in the Treatment of Periodontitis Stage III: A Pilot Randomized Controlled Clinical Trial

10.21203/rs.3.rs-45864/v1 ◽

2020 ◽

Author(s):

Alicia Morales ◽

Rafael Contador ◽

Joel Bravo ◽

Paola Carvajal ◽

Nora Silva ◽

...

Keyword(s):

Clinical Trial ◽

Stage Iii ◽

Treatment Modalities ◽

Controlled Clinical Trial ◽

Clinical Effects ◽

Scaling And Root Planing ◽

Pocket Depth ◽

Clinical Attachment Loss ◽

Root Planing

Abstract Background The aim of this triple- blind placebo- controlled parallel- arm randomized clinical trial was to evaluate the clinical effects of Lactobacillus rhamnosus SP1 or azithromycin as an adjunct to scaling and root planing (SRP) in patients with periodontitis stage III. Methods Forty-seven systemically healthy participants with periodontitis stage III were recruited. Following SRP, the participants were randomly assigned to one of three treatment modalities; 1) placebo (n = 15), 2) probiotics (n = 16) and 3) antibiotics-azithromycin (n = 16). The participants were monitored at baseline, 3, 6, 9 and 12 months after therapy. Probing pocket depth (PPD), bleeding on probing (BOP), clinical attachment loss (CAL) and plaque accumulation (PI) were evaluated. Results All 47 participants completed the study. At 12 months, all groups showed significant improvements of PPD and PI (p < 0.012) irrespective of the treatment modality and without significant differences between the groups. Probiotics and azithromycin showed no added benefit in terms of CAL. While the placebo (p = 0.002) and the antibiotic-azithromycin (p = 0.002) group showed a significant reduction of BOP, only the placebo group revealed a significant reduction of CAL at 12 months follow-up (p = 0.003). The number of sites and teeth with PPD ≥ 5, ≥6 and ≥ 7 mm were significantly reduced in all groups at 12 months follow-up (p < 0.025) irrespective of the treatment regime and without significant differences between the groups. Conclusion The use of probiotics or azithromycin as an adjunct to SRP failed to provide additional benefits in the treatment of periodontitis stage III. The benefits of these two treatment regimes as an adjunct to SRP remain unclear.

Download Full-text

Clinical Effects of the Local Drug Delivery Of 0.5% Azithromycin Gel in Treatment of Chronic Periodontitis Among Smokers Versus Non Smokers

Dental Journal of Advance Studies ◽

10.1055/s-0038-1672053 ◽

2016 ◽

Vol 04 (02) ◽

pp. 094-103

Author(s):

Jasmine Kaur ◽

Viniti Goel ◽

Ranjan Malhotra ◽

Vishakha Grover

Keyword(s):

Drug Delivery ◽

Chronic Periodontitis ◽

Alveolar Bone ◽

Local Drug Delivery ◽

Clinical Effects ◽

Scaling And Root Planing ◽

Pocket Depth ◽

Clinical Attachment Level ◽

Root Planing ◽

Attachment Level

Abstract Background: Along with conventional periodontal surgical therapy, local delivery of antibiotics may provide more effective treatment in smokers by targeting tissue-invasive bacteria. The aim of this randomized, clinical trial was to evaluate the adjunctive effects of subgingivally delivered 0.5% azithromycin (AZM) as an adjunct to scaling and root planing (SRP) in the treatment of chronic periodontitis in smokers versus non smokers. Methods: 38 sites in patients of chronic periodontitis were randomized and categorized into two treatment groups: Group 1 consisted of 19 sites in patients who were smokers and Group 2 consisted of 19 sites in non smokers, who received Scaling and Root Planing (SRP) plus 0.5% azithromycin gel Local drug delivery. Clinical parameters were recorded at baseline, 1 and 2 months. They included probing depth (PD) and clinical attachment level (CAL) and percentage bone fill. Results: Azithromycin resulted in significant improvements in both the groups. Mean decrease in PD in non smokers by the end of 2 months was 3.903mm and in smokers was 3.917mm. Gain in CAL in non smokers by the end of 2 months was 3.879mm and in smokers it was 3.920mm. Mean bone fill at one month for smokers was 15.86% and was 26.58% at 2 months. In non-smokers the mean bone fill was 17.19% at 1 month and 24.03% at 2 months. Conclusions: When compared to the non smokers, the adjunctive use of 0.5% AZM resulted in similar improvement in clinical outcome in the treatment of chronic periodontitis among smokers. Local drug delivery of Azithromycin gel contributed to decrease in probing pocket depth, gain in clinical attachment level and in alveolar bone. The apparent bone regeneration also raises the intriguing possibility that Azithromycin encourages bone formation once tissue inflammation has subsided.

Download Full-text

Clinical effects of probiotic or azithromycin as an adjunct to scaling and root planing in the treatment of periodontitis stage III: A pilot randomized controlled clinical trial

10.21203/rs.3.rs-45864/v3 ◽

2020 ◽

Author(s):

Alicia Morales ◽

Rafael Contador ◽

Joel Bravo ◽

Paola Carvajal ◽

Nora Silva ◽

...

Keyword(s):

Clinical Trial ◽

Stage Iii ◽

Treatment Modalities ◽

Controlled Clinical Trial ◽

Clinical Effects ◽

Scaling And Root Planing ◽

Pocket Depth ◽

Clinical Attachment Loss ◽

Root Planing

Abstract Background: The aim of this triple- blind placebo- controlled parallel- arm randomized clinical trial was to evaluate the clinical effects of Lactobacillus rhamnosus SP1 or azithromycin as an adjunct to scaling and root planing (SRP) in patients with stage III periodontitis.Methods: Forty-seven systemically healthy participants with stage III periodontitis were recruited. Following SRP, the participants were randomly assigned to one of three treatment modalities; 1) placebo (n=15), 2) probiotics (n=16) and 3) antibiotics-azithromycin (n=16). The participants were monitored at baseline, 3, 6, 9 and 12 months after therapy. Probing pocket depth (PPD), bleeding on probing (BOP), clinical attachment loss (CAL) and plaque accumulation (PI) were evaluated. Results: All 47 participants completed the study. At 12 months, all groups showed significant improvements of PPD and PI (p<0.012) irrespective of the treatment modality and without significant differences between the groups. Probiotics and azithromycin showed no added benefit in terms of CAL. While the placebo (p=0.002) and the antibiotic-azithromycin (p=0.002) group showed a significant reduction of BOP, only the placebo group revealed a significant reduction of CAL at 12 months follow-up (p=0.003). The number of sites and teeth with PPD ≥5, ≥6 and ≥7mm were significantly reduced in all groups at 12 months follow-up (p<0.025) irrespective of the treatment regime and without significant differences between the groups. Conclusion: The use of probiotics or azithromycin as an adjunct to SRP failed to provide additional benefits in the treatment of stage III periodontitis. The benefits of these two treatment regimes as an adjunct to SRP remain unclear. Trial Registration: NCT02839408, 10/28/2017, Clinicaltrial.gov.

Download Full-text